News

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies competed for a coveted spot in the Grand Finals. The five finalists are developing medical technology innovations in remote monitoring, patient safety and satisfaction, and prevention:

  • Alva Health (New Haven, CT) is developing a real-time, wearable stroke monitor for older Americans living with high stroke risk.
  • BioDevek (Brookline, MA) is developing an endoscopically-sprayable adhesive hydrogel to seal and protect surgical lesions after polyp removal.
  • Caretaker Medical (Charlottesville, VA ) is developing a wireless finger sensor for continuous “beat by beat” blood pressure and hemodynamics remote monitoring.
  • Cooler Heads Care (San Diego, CA) is developing an affordable wearable device so chemo patients can keep their hair.
  • Nutromics (Brunswick, AUS) is developing a wearable continuous molecular monitoring platform that can track drugs, hormones, metabolites, and proteins.

The final competition will be both live in-person as well as livestreamed on Wednesday, Sept. 29 at 12:00 PM ET during the The MedTech Conference. Viewers will vote online and in-person to decide who takes home the $350,000 Grand Prize and title of MedTech Innovator 2021. Register to watch the competition livestream here.

Recent News

03/12/2026

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, a rare

03/11/2026

ATCC Secures NIAID Contract to Strengthen U.S. Preparedness Against Emerging Infectious Diseases

ATCC has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract (number 75N93025D00017) with an ordering period of 7 years with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). The contract, with an initial

03/10/2026

ivWatch and Aon Address Costly and Underreported Patient Harm Epidemic with New Return on Investment Model

ivWatch, the IV safety company, has partnered with Aon, a leading global insurance broker and risk consultant, to quantify the clinical and financial impact of severe IV infiltration and extravasation injuries – one of the most underreported and costly adverse events in healthcare – and to model the return on investment associated with detecting these